Literature DB >> 30075233

In-vitro and in-vivo antileishmanial activity of inexpensive Amphotericin B formulations: Heated Amphotericin B and Amphotericin B-loaded microemulsion.

Andreza Rochelle do Vale Morais1, André Leandro Silva2, Sandrine Cojean3, Kaluvu Balaraman4, Christian Bories3, Sébastien Pomel3, Gillian Barratt5, Eryvaldo Sócrates Tabosa do Egito6, Philippe M Loiseau7.   

Abstract

Amphotericin B (AmB) is effective against visceral leishmaniasis (VL), but the renal toxicity of the conventional form, mixed micelles with deoxycholate (M-AmB), is often dose-limiting, while the less toxic lipid-based formulations such as AmBisome® are very expensive. Two different strategies to improve the therapeutic index of AmB with inexpensive ingredients were evaluated on this work: (i) the heat treatment of the commercial formulation (H-AmB) and (ii) the preparation of an AmB-loaded microemulsion (ME-AmB). M-AmB was heated to 70 °C for 20 min. The resulting product was characterized by UV spectrophotometry and circular dichroism, showing super-aggregates formation. ME-AmB was prepared from phosphate buffer pH 7.4, Tween 80®, Lipoid S100® and Mygliol 812® with AmB at 5 mg/mL. The droplet size, measured by dynamic light scattering, was about 40 nm and transmission electron microscopy confirmed a spherical shape. Rheological analysis showed low viscosity and Newtonian behavior. All the formulations were active in vitro and in vivo against Leishmania donovani (LV9). A selectivity index (CC50 on RAW/IC50 on LV9) higher than 10 was observed for ME-AmB, H-AmB and AmBisome®. Furthermore, no important in vivo toxicity was observed for all the samples. The in-vivo efficacy of the formulations after IV administration was evaluated in Balb/C mice infected with LV9 (three doses of 1 mg/kg AmB) and no significant difference was observed between H-AmB, M-AmB, ME-AmB and AmBisome®. In conclusion, these two inexpensive alternative formulations for AmB showing good efficacy and selectivity for Leishmania donovani merit further investigation.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Amphotericin B; Microemulsion; Superaggregates; Visceral leishmaniasis

Mesh:

Substances:

Year:  2018        PMID: 30075233     DOI: 10.1016/j.exppara.2018.07.017

Source DB:  PubMed          Journal:  Exp Parasitol        ISSN: 0014-4894            Impact factor:   2.011


  3 in total

Review 1.  Lipid Systems for the Delivery of Amphotericin B in Antifungal Therapy.

Authors:  Célia Faustino; Lídia Pinheiro
Journal:  Pharmaceutics       Date:  2020-01-01       Impact factor: 6.321

2.  Topical Amphotericin B Semisolid Dosage Form for Cutaneous Leishmaniasis: Physicochemical Characterization, Ex Vivo Skin Permeation and Biological Activity.

Authors:  Diana Berenguer; Mª Magdalena Alcover; Marcella Sessa; Lyda Halbaut; Carme Guillén; Antoni Boix-Montañés; Roser Fisa; Ana Cristina Calpena-Campmany; Cristina Riera; Lilian Sosa
Journal:  Pharmaceutics       Date:  2020-02-12       Impact factor: 6.321

3.  Nanoassemblies from Amphiphilic Sb Complexes Target Infection Sites in Models of Visceral and Cutaneous Leishmaniases.

Authors:  Juliane S Lanza; Virginia M R Vallejos; Guilherme S Ramos; Ana Carolina B de Oliveira; Cynthia Demicheli; Luis Rivas; Sébastien Pomel; Philippe M Loiseau; Frédéric Frézard
Journal:  Pharmaceutics       Date:  2022-08-21       Impact factor: 6.525

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.